Baidu
map

吸烟、心率与缺血性卒中:一项中国内蒙古人群的前瞻性队列研究

2014-06-26 MedSci MedSci原创

2013年7月23日Stroke在线发表了苏州大学医学部公共卫生学院张永红教授团队的研究报告“吸烟、心率与缺血性卒中:一项中国内蒙 古人群的前瞻性队列研究”(Xu T, Bu X, Li H,et al. Smoking, heart rate, and ischemic stroke: a population-based prospective cohort study among in

2013年7月23日Stroke在线发表了苏州大学医学部公共卫生学院张永红教授团队的研究报告“吸烟、心率与缺血性卒中:一项中国内蒙 古人群的前瞻性队列研究”(Xu T, Bu X, Li H,et al. Smoking, heart rate, and ischemic stroke: a population-based prospective cohort study among inner Mongolians in China. Stroke,2013,44:2457-2461.)。

卒中在全球范围位于各疾病死亡原因的第二位,长期致残原因的首位。在中国,缺血性卒中是卒中最常见的类型。吸烟是一个严重的公众健康问题,也是心血管疾病的重要危险因素。既往研究显示,吸烟可能 是缺血性卒中的独立危险因素,同时心率在缺血性卒中的发生中也可能扮演重要角色。目前并没有系统评价中国人群吸烟、心率与缺血性卒中相互关系的相关研究。 此项研究在中国内蒙古人群中评估了吸烟、心率与缺血性卒中发病率的相关累积效应。

这项前瞻性队列研究纳入2530名大于20岁的内蒙古成人按吸烟状态和心率分为四个亚组进行分析。多元COX回归分析发现与不吸烟且心率小于80次(参考组)相比,不吸烟伴心率大于80次,吸烟心率小于80次,吸烟心率大于80次的缺血性卒中风险分别为: 1.42 (0.62-3.28), 2.11 (1.06-4.23), and 2.86 (1.33-6.14)。吸烟与快心率可能是卒中的重要风险因素。

原始出处:
Xu T, Bu X, Li H, Zhang M, Wang A, Tong W, Xu T, Sun Y, Zhang Y.Smoking, heart rate, and ischemic stroke: a population-based prospective cohort study among Inner Mongolians in China.Stroke. 2013 Sep;44(9):2457-61

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1892619, encodeId=b164189261976, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 30 08:43:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954307, encodeId=025c195430e5b, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Nov 16 06:43:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898709, encodeId=806e1898e0995, content=<a href='/topic/show?id=e12930529ee' target=_blank style='color:#2F92EE;'>#内蒙古#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30529, encryptionId=e12930529ee, topicName=内蒙古)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Feb 25 04:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937612, encodeId=7412193e612a7, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Feb 18 17:43:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805993, encodeId=d8c51805993d9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Sep 28 04:43:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006355, encodeId=7753200635585, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Dec 20 23:43:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1892619, encodeId=b164189261976, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 30 08:43:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954307, encodeId=025c195430e5b, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Nov 16 06:43:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898709, encodeId=806e1898e0995, content=<a href='/topic/show?id=e12930529ee' target=_blank style='color:#2F92EE;'>#内蒙古#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30529, encryptionId=e12930529ee, topicName=内蒙古)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Feb 25 04:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937612, encodeId=7412193e612a7, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Feb 18 17:43:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805993, encodeId=d8c51805993d9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Sep 28 04:43:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006355, encodeId=7753200635585, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Dec 20 23:43:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1892619, encodeId=b164189261976, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 30 08:43:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954307, encodeId=025c195430e5b, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Nov 16 06:43:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898709, encodeId=806e1898e0995, content=<a href='/topic/show?id=e12930529ee' target=_blank style='color:#2F92EE;'>#内蒙古#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30529, encryptionId=e12930529ee, topicName=内蒙古)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Feb 25 04:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937612, encodeId=7412193e612a7, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Feb 18 17:43:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805993, encodeId=d8c51805993d9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Sep 28 04:43:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006355, encodeId=7753200635585, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Dec 20 23:43:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]
    2015-02-25 xugumin
  4. [GetPortalCommentsPageByObjectIdResponse(id=1892619, encodeId=b164189261976, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 30 08:43:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954307, encodeId=025c195430e5b, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Nov 16 06:43:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898709, encodeId=806e1898e0995, content=<a href='/topic/show?id=e12930529ee' target=_blank style='color:#2F92EE;'>#内蒙古#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30529, encryptionId=e12930529ee, topicName=内蒙古)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Feb 25 04:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937612, encodeId=7412193e612a7, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Feb 18 17:43:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805993, encodeId=d8c51805993d9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Sep 28 04:43:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006355, encodeId=7753200635585, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Dec 20 23:43:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1892619, encodeId=b164189261976, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 30 08:43:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954307, encodeId=025c195430e5b, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Nov 16 06:43:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898709, encodeId=806e1898e0995, content=<a href='/topic/show?id=e12930529ee' target=_blank style='color:#2F92EE;'>#内蒙古#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30529, encryptionId=e12930529ee, topicName=内蒙古)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Feb 25 04:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937612, encodeId=7412193e612a7, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Feb 18 17:43:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805993, encodeId=d8c51805993d9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Sep 28 04:43:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006355, encodeId=7753200635585, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Dec 20 23:43:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1892619, encodeId=b164189261976, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 30 08:43:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954307, encodeId=025c195430e5b, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Nov 16 06:43:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898709, encodeId=806e1898e0995, content=<a href='/topic/show?id=e12930529ee' target=_blank style='color:#2F92EE;'>#内蒙古#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30529, encryptionId=e12930529ee, topicName=内蒙古)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Wed Feb 25 04:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937612, encodeId=7412193e612a7, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Feb 18 17:43:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805993, encodeId=d8c51805993d9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Sep 28 04:43:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006355, encodeId=7753200635585, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Dec 20 23:43:00 CST 2014, time=2014-12-20, status=1, ipAttribution=)]

相关资讯

ASCO 2014:单核苷酸多态性与吸烟状况对非小细胞肺癌的预测

摘要号:1563 第一作者:吴俊杰,上海长海医院呼吸内科 标题:单核苷酸多态性与吸烟状况对非小细胞肺癌的预测 背景:肺癌已成为死亡率最高的恶性肿瘤。其5年生存率小于15%,但早期肺癌患者经过有效治疗其5年生存率可高达87.7%,由此可见,早期肺癌的及早诊断是影响肺癌患者生存率的关键。然而,当前肺癌的诊断水平并不能够提高早期肺癌的检出率。本研究的目的在于引入单核苷酸多态性(SNPs

BJSM:缺乏运动与吸烟相比更易导致心血管疾病

澳大利亚的一组研究表明: 30岁以上的妇女中,缺乏运动锻炼引起心血管疾病的发生率比肥胖、高血压、吸烟引起的都要高。这项研究近期由澳大利亚学者Wendy J. Brown博士发表在BJSM上。Wendy J. Brown博士指出,增强和保持体育锻炼的措施对改善公众的健康更有好处,对女性尤其如此。此前,有研究列出全球排名前10的致病因子,高血压位居榜首,接下来就是吸烟,和固体燃料引起的空气污染。但是,

Pediatrics:兴奋剂治疗多动症或可降低患者吸烟风险

卡罗莱纳州达勒姆市——据杜克大学医学院研究人员领导的一份研究分析说,使用兴奋剂类药物治疗注意缺陷多动障碍(ADHD,简称多动症)或可降低吸烟风险,特别是在持续用药的情况下会有这样的效果。 《儿科》杂志网络版在2014年5月12日发表了这一研究成果。【原文下载】 “由于患有多动症的人更容易吸烟,我们的研究支持使用兴奋剂治疗以减少多动症青少年吸烟的可能性。”资深作家、杜克大学ADHD项目主

世卫组织敦促中国加大力度使用烟盒大面积图示警示标志

2014年4月8日 研究显示,如果中国在烟盒上使用大幅图形健康警示,将提高人们对吸烟危害的认识,有助于降低吸烟率,从而拯救生命。这些是世界卫生组织与国际烟草控制政策评估项目4月8日发布的一份新报告中的主要结论。 世界卫生组织题为《中国的烟草健康警示——有效性的证据和对行动的指导意义》的报告指出,全世界的证据均显示,大幅图形警示显著提高烟盒警示标识的有效性,增强人们对卷烟

Nat Genet:携带BRCA2突变的吸烟者更易患上肺癌

最近的一项新研究证实,BRCA2和CHEK2基因变异,特别是突变型BRCA2,可以大大增加个人患肺癌的风险。如果吸烟者携带BRCA2变异,其患肺癌的风险可能翻倍。 由伦敦癌症研究所、法国国际癌症研究机构、美国国家癌症研究所和美国达特茅斯学院等研究结构组成的国际合作小组,利用来自1000个肺癌遗传学研究基因组项目的综合结果,完成了这一研究,相关结果发表在2014年6月1日的《自然遗传学》(Natu

GIE:代谢综合征的男性吸烟患者行结直肠癌筛查非常必要

在过去四十年,美国的结直肠癌发病率降低很大程度上归功于有效的筛查。研究表明小于50岁尤其是40-49岁人群结直肠癌的发病率在上升,可能与该年龄段人群代谢紊乱性疾病及肥胖的发生率偏高有关。证据表明早期发现病灶并治疗能大大降低结直肠癌的发病率及相关死亡。目前绝大部分指南推荐对50岁以上的人群(不管性别、有无危险因素)进行结直肠癌筛查,有结直肠癌的家族史者除外。 台湾国立医院内科系的Li-Chun C

Baidu
map
Baidu
map
Baidu
map